Company profile
UK company 04793696, incorporated on 10 June 2003.
Breakthrough Science for Severe Viral Lung Infections - Synairgen
Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Discover SNG001, our breakthrough treatment for COVID-19.
Company number 04793696
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
AA | Transaction MzU0MDA2MTQ0MmFkaXF6a2N4 | Paper/PDF filed
Published 26 Aug 2026 22:44
AD01 | Transaction MzUzMTQ4MDE3NGFkaXF6a2N4
Published 09 Jul 2026 12:10
Company registered at Companies House
Synairgen is a drug discovery and development company specialising in respiratory diseases with a focus on asthma and chronic obstructive pulmonary disease (COPD). It was spun out of the University of Southampton in 2003. A small lean and highly focused company to develop new respiratory drugs. Most of our effort is now focused on an inhaled formulation of IFN beta for treating severe virus-induced exacerbations of asthma and COPD as well as hospital-based influenza admissions.; http://www.synairgen.com/
Successful preclinical and Phase 1 development of inhaled interferon beta for treatment of virus-induced asthma exacerbations. We are entering phase 2a for asthma and COPD indications after a successful 2nd fund raising round in early 2009.
